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Abstracts / Pediatric Hematology Oncology Journal 1 (2016) S1eS33S14MRD samples, PI-MRD were 130 (79.3%), PC-MRD were 24 (14.6%) and SFU
were 10 (6.1%). Of 130 PI-MRD, 40% samples were positive with median of
0.21% and range 0.0006% to 48.3%. Of 52 PI-MRD-positive cases, PC-MRD
was performed in 46.2% cases and was positive in 62.5% cases (median,
0.075% & range, 0.007-21.5%). Of 10 SFU samples, MRD was positive in 2
cases. Of 130 diagnostic samples, < 2 LAIPs were seen in only 1% and >6
LAIPS in 2% (median LAIPs, 4 & range, 1-8). Similarly, of 164 MRD samples,
four had <2 LAIP (2.4%) and labelled as “suspicious” and in 69 MRD-pos-
itive samples 2-LAIPS were only 7.1%. Furthermore, in 15 samples with
MRD-positive 0.01% and >1.5 million acquired-events, the results were
compared between time-gated initial 500000-events, 1000000 events and
all events acquired. In these 10 samples, eight samples found to be nega-
tive in initial 500000-events and four in initial 1000000-events (as the
number of MRD-events were < 20) highlighting the importance of
acquisition of >1.5 million cells to increase the sensitivity of FC-MRD assay.
Conclusion: We established a cost-effective 10-color single tube FC-MRD
assay with high sensitivity of 1 in 105 and applicability in >97% MRD
samples. Our study showed that acquisition of events less or equal to 1
million cells can reduce the sensitivity of FC-MRD assay.Table 1
Main-MRD-tube Nuclear-dye-tube
Fluorochrome Antibody Clone Company Antibody Clone Company
BV421 CD123 9F5 BD
BV510 CD20 2H7 BD
FITC CD58 AICD58 BC SYTO13 — INVITROGEN
PE CD86 FUN-1 BD
PE-CF594 CD25 M-A251 BD
PC5.5 CD19 J3-119 BC CD19 J3-119 BC
PC7 CD10 ALB1 BC
APC CD34 581 BD
APC-A700 CD45 J.33 BC CD45 J.33 BC
APC-A750 CD38 LS198-4-3 BCMyeloid Malignancies
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Background: Optimal management of infectious complication is the
biggest challenge in children receiving chemotherapy for acute myeloid
leukemia (AML) especially during the induction phase. Signiﬁcant
improvement in overall survival worldwide has been due to advances in
supportive care. The aim of this study is to assess the changing pattern of
blood stream infections (BSI) during AML induction chemotherapy over
the last decade and to analyse the burden of supportive care in managing
these infections.
Material and Methods: The study is a retrospective analysis of children
undergoing AML induction chemotherapy at our centre from 2002 to 2015.
Results: A total of ﬁfty four children had received induction chemotherapy
as per UK MRC protocol were included in the study. Ninety six episodes of
febrile neutropenia were studied. Fifty septic events were recorded and in
twenty seven such episodes children had to be shifted to paediatric inten-
sive care for either ventilatory or ionotropic support. Blood culture proven
septic episodes were seen in 37% of the children, of which 87% were due to
gram negative organisms. High end antibiotics like colistin / tigecycline
were used in 38% of these children. Neutropenic enterocolitis was the most
common focus of infection in these children. Remissionwas achieved in 85%
of children at end of induction and the mortality rate was 10%.
Between the years 2012 to 2015 the incidence of drug resistant gram
negative sepsis had risen to 87% when compared to 20% during the 2002 to2011 period. Though the mortality rates had remained the same in both
groups, the morbidity due to therapy including the duration of hospital
stay, the need for paediatric intensive care support, the use of colistin for
carbapenam resistant infections and the use of granulocyte transfusions to
help tide over the sepsis had dramatically increased.
Conclusion: Western data has shown a rising trend in gram positive in-
fections during AML induction. However, our study has shown predomi-
nantly gram negative infections. The last 5 years has shown a clear increase
in carbapenam resistant Klebsiella infections. This has increased the cost of
therapy signiﬁcantly. Several interventions have been introduced at our
unit to reduce the incidence and mortality due to drug resistant gram
negative sepsis. An active infection control policy with strict surface
cleaning, education of personnel on hand hygiene and restricting unnec-
essary use of high end antibiotics had been the ﬁrst measure. Surveillance
of children for Carbapenem resistance (Carba-R) organisms at the start of
induction therapy has helped identify children at risk. Early introduction of
colistin in Carba-R positive children during febrile neutropenic episodes
has been the main intervention to reduce mortality. The introduction of
neutropenic diet which is lactose and gluten free during the mucositisphase has helped reduce translocation of intestinal bacteria. Early use of
granulocytes in the ﬁrst 48 hours of onset of septic shock has helped as a
bridge till neutrophil recovery.
These measures have kept the mortality rates constant at 10% over the last
decade. However, it comes with a signiﬁcant increase in the cost of sup-
portive care during AML induction.Ă
